PHARMING GRP SP. ADRS Cash Flow Conversion Efficiency
PHARMING GRP SP. ADRS cash flow conversion efficiency. Based on the latest financial reports, PHARMING GRP SP. ADRS (PHG) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.71 Million ≈ $12.52 Million USD) by net assets (€277.10 Million ≈ $323.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PHARMING GRP SP. ADRS (2021–2025)
Cash flow conversion efficiency of PHARMING GRP SP. ADRS from 2021 to 2025. This chart illustrates how PHARMING GRP SP. ADRS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PHG live share price for real-time trading data and today's change.
PHARMING GRP SP. ADRS Cash Flow Conversion Ratio Explained
PHARMING GRP SP. ADRS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PHARMING GRP SP. ADRS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PHARMING GRP SP. ADRS ranked by their cash flow conversion efficiency. Also see PHARMING GRP SP. ADRS market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Argo Properties NV
TA:ARGO
|
0.019x |
|
Replimune Group Inc
NASDAQ:REPL
|
-0.313x |
|
Shanghai Huitong Energy Co Ltd
SHG:600605
|
-0.034x |
|
Dongfeng Electronic Technology Co Ltd
SHG:600081
|
0.063x |
|
EuroTeleSites AG
F:7YF
|
N/A |
|
Arena REIT
AU:ARF
|
0.027x |
|
Qiming Information Technology Co Ltd
SHE:002232
|
-0.005x |
|
Metallus, Inc
NYSE:MTUS
|
-0.039x |
Annual Cash Flow Conversion Efficiency for PHARMING GRP SP. ADRS (2021–2025)
The table below shows the annual cash flow conversion efficiency of PHARMING GRP SP. ADRS from 2021 to 2025. Review how much free cash does PHARMING GRP SP. ADRS generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €277.10 Million ≈ $323.96 Million |
€54.71 Million ≈ $63.96 Million |
0.197x | +2531.41% |
| 2024-12-31 | €221.06 Million ≈ $258.44 Million |
€-1.79 Million ≈ $-2.10 Million |
-0.008x | +89.73% |
| 2023-12-31 | €218.78 Million ≈ $255.78 Million |
€-17.30 Million ≈ $-20.23 Million |
-0.079x | -172.06% |
| 2022-12-31 | €204.64 Million ≈ $239.24 Million |
€22.46 Million ≈ $26.26 Million |
0.110x | -44.05% |
| 2021-12-31 | €192.92 Million ≈ $225.54 Million |
€37.84 Million ≈ $44.24 Million |
0.196x | -- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more